Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

WZWei ZhaoXCXingyu CaoDLDeyan Liu

Discussion

Loading...

Member takes

Overview

Results show no reduction in graft-versus-host disease risk in aplastic anemia patients receiving haploidentical hematopoietic stem cell transplantation, suggesting limited efficacy of third-party inf

Key Points

  • The combination of third-party cell infusion did not improve graft-versus-host disease incidence in aplastic anemia patients.
  • No instances of primary graft failure were reported among the analyzed patients with a median follow-up of 46.4 months.
  • Assessment involved hematopoietic stem cell transplantation across cohorts, analyzing effects on survival rate and GVHD.
  • Findings suggest that third-party infusion may not enhance transplantation efficacy in this patient group.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e523https://doi.org/10.1182/blood-2025-2495
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia2025
  2. 2A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia2025
  3. 3Superior outcome from frontline cord blood transfusion combined HLA-full-matched unrelated donor hematopoietic stem cell transplantation for aplastic anemia2025 · 1 citations
  4. 4The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia：a retrospective study.2025
  5. 5[Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia].2025